June 2021
Construction begins
Our VisionTo be the preferred partner for the world’s leading specialty pharmaceutical and generic companies.
Our misionOperating a State-Of-The-Art US FDA, EU GMP compliant finished formulations facility bolstered by a team of the best scientists, engineers, and professionals in India.
Our Values
Collaboration
Innovation &
science-based
decisions
Accountability
Agility
Sustainability
Key Timeline
July 2023
Installation and validation of process equipment
October 2023
Facility scheduled to be operational
April 2025
Successful USFDA
Inspection - 1
November 2025
Successful EUGMP Inspection
April 2026
Successful USFDA
Inspection - 2
Innoxel is a USFDA and EUGMP approved Contract Development and Manufacturing Organization (CDMO) based in Vadodara, India specializing in aseptic as well as terminal sterilized production of injectable vials, pre-filled syringes, and oral liquids.
An integrated pharmaceutical company, Innoxel Lifesciences is equipped with Research & Formulation Development as well as manufacturing capabilities for complex drug-delivery formulations in niche therapies of oncology & critical care.
Focusing on regulated markets such as the USA, EU and Canada we aim to offer high-quality finished formulation manufacturing support to the worlds leading pharmaceutical companies delivering unparalleled quality standards.
Established in 2020, Innoxel Lifesciences stands out as a unique greenfield site. We have meticulously planned, constructed, and are currently operational, ensuring adherence to EU GMP, UK MHRA, and US FDA standards. With two successful USFDA and a EUGMP inspection under our belt, Innoxel has started supplying commercial products to regulated products, with multiple products and filings to follow.
